Opioids are the class of drugs that include illicit drugs such as heroin, codeine, fentanyl, meperidine, methadone, morphine, hydrocodone, diphenoxylate, hydromorphone, methylphenidate, oxycodone, and oxymorphone. Opioids are prescribed for pain management and treatment of cough and diarrhea. According to the survey conducted by Center for Behavioral Health Statistics and Quality (CBHSQ), in 2015, out of 20.5 million around 2 million (10%) Americans of 12 years age or older, which had a substance use disorder were on pain relievers and around 591,000 were on heroin.
Crisis in the U.S. Opioids Market According to the New York Times analysis of state data, in 2016, drug overuse led to death of 59,000 to 65,000 people in the U.S. Around two-third of these deaths were due to opioids overuse and the number is expected to increase. According to a survey of National Institute of Drug Abuse (NIDA), deaths due to the overdose prescription of opioid pain relievers have more than tripled in the past 20 years, escalating to 16,651 deaths in the U.S. in 2010. It can be concluded from the analysis of the data (data from the survey and New York Times data), that death due to opioids have more than doubled in the past six years. In October 2016, the U.S. government declared opioids crisis as an emergency to increase awareness among the public about overuse of opioids. The crisis also restricts doctors and pharmacy stores from over-prescribing or overstocking opioids. Furthermore, the government has approached leading pharmacy chains, insurance companies, and others for cooperation against opioid crisis. For instance, Attorney General of over 35 states sent a letter to the America’s Health Insurance Plans, national association whose members provide coverage for health care and related services, urging its members to reconsider coverage policies that may be fueling the opioid crisis in October 2017. Such measures can ensure proper usage of opioids and favor the market players in the U.S. The U.S. opioids market was valued at US$ 12,046.3 million in 2015 and is expected to witness a moderate CAGR of 5.2% during the forecast period (2016–2024). Request A Sample Copy: http://bit.ly/2Mp9Tar According to the American Academy of Pain Medicine (AAPM), 2011, around 1.8 billion people suffered from chronic pain. Moreover, according to the National Institute of Health (NIH) estimates in 2015, one in 10 people in the U.S. suffered from chronic pain. Increasing prevalence of chronic pain is expected to result in high prescription of opioids pain relievers, which in turn is expected to fuel the market growth. Easy availability and favorable insurance policy are other major drivers for growth of the U.S. opioids market. The analysis of Medicare prescription drug plans, which covers 35.7 million people in the second quarter of 2017, by ProPublica — an investigative journal and The New York Times — a leading U.S. newspaper, revealed that only one-third of the covered people had any access to other types of pain killer and less-risky opioids. This was attributed to low cost of opioids drugs. The scenario might change, however, due to strict monitoring from government and regulatory bodies. Cannabis as potential alternative for pain relief can be a threat to the U.S. opioids market Cannabis could be the alternative therapy for opioids. Currently, medical marijuana is legal in 28 states and the District of Columbia even though it is illegal under federal law. According to a research published in Annals of Internal Medicine, in majority of cases, between 45% and 85%, medical marijuana is used for pain management. However, there is some ambiguity about medical marijuana effectiveness in pain management. Cannabis could be used as effective therapy after establishment of clinical trials. Some major players operating in the U.S. opioids market include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals plc, Allergan, plc, and Pfizer Inc. Click To Reading More On U.S. Opioids Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]
0 Comments
Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.
Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-sample/2053 Major symptoms of dermatophytic onychomycosis include thickening and whitening of nails. Moreover, the nails become brittle and appear white as the infection progresses. People suffering from diabetes, peripheral vascular disease, HIV, immune suppression, obesity, and geriatric population are at increased risk of this common fungal infection. Dermatophytic onychomycosis could be treated with either topical preparations or oral antifungal agents based on the severity of infection. The treatment often lasts for an average period of six months. In recent past, advancement in therapy with the introduction of effective topical and oral products has controlled the rapid spread of dermatophytic onychomycosis. The global dermatophytic onychomycosis treatment market size was valued at US$ 2,596.8 million in 2017, and is expected to witness a CAGR of 12.6% over the forecast period (2018 – 2026). Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth. Development of new therapies that aid in treatment of dermatophytic onychomycosis is expected to drive growth of the dermatophytic onychomycosis treatment market over the forecast period Introduction of new drug candidates and adoption of new treatment approaches is a major factor contributing to the dermatophytic onychomycosis treatment market growth. For instance, in 2014, the U.S. Food and Drug Administration (FDA) approved two new topical antifungal drugs—efinaconazole and tavaborole— for the treatment of dermatophytic onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes. Efinaconazole is the first approved topical triazole antifungal agent and tavaborole is the first approved oxobarole antifungal agent for this indication. These agents offer short treatment courses, high cure rates, and few relapse cases. Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc., Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and Merz Pharma. Detailed Segmentation: Global Dermatophytic Onychomycosis Treatment Market, By Therapy Type:
Global Dermatophytic Onychomycosis Treatment Market, By End User:
Global Dermatophytic Onychomycosis Treatment Market, By Geography:
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/dermatophytic-onychomycosis-treatment-market-2053 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Tylosin is used in livestock for various purposes such as a feed additive for growth promotion and as an antibiotic against infectious diseases in animals such as chickens, turkeys, felines, canines, pigs, calves, and others. These antibiotics aid in the treatment of chronic respiratory disease (CRD) associated with Mycoplasma Gallisepticum and Mycolplasma synoviae and other infections.
Tylosin is used for treatment and control of swine dysentery associated with Brachyspira Hyodysenteriae and for the control of porcine proliferate enteropathies in pigs. Moreover, Tylosin is highly effective in tylosin-responsive diarrhea in dogs, which is a canine chronic, recurrent diarrhea that responds repeatedly to Tylosin treatment. Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2061 Market Dynamics The global Tylosin market is expected to witness significant growth over the forecast period, owing to rising demand for Tylosin in livestock industry. For instance, according to a study by Ministry for Primary Industries, New Zealand 2016, Tylosin accounted for over 83% of macrolide and lincosamide sales during 2011 and 2014 and the trend is expected to continue over the forecast period. Moreover, certain mergers and acquisitions are expected to boost the market growth over the forecast period. For instance, Eily, Lilly, and Company acquired Novartis Animal Health in 2014. Varied product offering by manufacturers such as Elanco Animal Health is expected to propel the global Tylosin market growth over the forecast period. For instance, Elanco offers Component with Tylan, an implant line with initial and terminal implants for steers and heifers. This implant includes a tylosin tartrate (Tylan) pellet that dissolves and releases antibacterial throughout the implant site. The global Tylosin market size was valued at US$ 379.0 million in 2017, and is expected to witness a CAGR of 1.2% over the forecast period (2018 – 2026). Increasing demand for healthy livestock is expected to support growth of global Tylosin market over the forecast period The demand for livestock animals for consumption is on the rise worldwide and is expected to maintain the positive growth in demand over the forecast period. Subsequently, the demand for infection-free and healthy livestock used primarily for consumption is increasing. However, the prevalence of various microbial infections is high in both humans and animals. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, zoonotic diseases are common in the U.S. and worldwide and over 6 out of every 10 known infectious diseases in humans are spread from animals. Hence, antibiotics are an important medication for livestock that aide in providing healthy food products for consumption in humans. Key players operating in the global Tylosin market include Zoetis, Tairui Pharmaceuticals, Lukang Pharmaceutical, Henan Hualun, Qilu Pharmaceutical (Inner Mongolia) Co., Ltd, Huvepharma, AdvaCare Pharma, and Elanco Animal Health. Detailed Segmentation: Global Tylosin Market, By Drug Type:
Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/tylosin-market-2061 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Holter monitor is a battery-operated portable device that measures and records cardiac activity for 24 to 48 hours. Holter monitors device are used to detect and analyze cardiac arrhythmia, atrial fibrillation, and bradycardia. The device has silver dollar-sized electrodes, which can be attached to patients. The device is powered by small battery electrocardiogram (ECG) appliance. The system is incorporated with recorder and software to record heart rhythm and analyze the recorded data respectively. It is majorly used in patients diagnosed with coronary artery disease or post infarction period. According to the American Heart Association, around 17.3 million deaths are caused due to cardiovascular disease worldwide annually and number is anticipated to reach around 23.6 million by 2030. Increasing prevalence of cardiovascular disorders, adoption of preventive healthcare measures by population are key drivers for growth of global holter monitoring market.
Holter Monitor Market Taxonomy On the basis of Product Type, Holter Monitor Market is segmented into:
https://www.coherentmarketinsights.com/insight/request-sample/937 Increasing prevalence of cardiovascular diseases around the globe is expected to fuel growth of the holter monitor market over the forecast period On the basis of Geography, Holter Monitor Market is segmented into North America, Latin America, Asia Pacific, Middle East and Europe. Increasing geriatric population and adoption of advanced healthcare facilities by patients are major factors expected to drive the growth of global cardiac holter monitor market over the forecast period. Geriatric population is more prone to heart diseases as heart muscles loose the resistance and capability to respond to different pressure rates, in turn making them more susceptible to cardiac disorders. According to the Center for Disease Control and Prevention (CDC), in 2012, around 117 million adults were suffering from one or more chronic conditions. North America holds dominant position in holter monitor market, owing high adoption of minimally aggressive diagnostic tools by patients and supportive government regulations and funding for treatment of cardiovascular disorder. According to the report published by American Heart Association in 2015, an estimated 450,000 deaths due to cardiac disorders in the U.S. The holter monitor device market of Asia Pacific region is expected to grow at significant rate over the forecast period, owing to increasing prevalence of chronic disorder cases and unhealthy nutrition habits among rural population. Increasing awareness regarding treatment of cardiac arrhythmia and atrial fibrillation along with various programs conducted by world health organization (WHO) for prevention of cardiovascular disorders are major factors fueling growth of the holter monitor market in Asia Pacific. Integration of advanced technologies in medical devices is expected to boost growth of the market. For instance, in 2015, Philips healthcare incorporated wireless and Bluetooth technology in cardiac hotler monitoring device. Shifting manufactures method towards customer centric development of products is expected to propel growth of the global holter monitor market over the forecast period. Key players operating holter equipment market include GE Healthcare, FUKUDA DENSHI, Koninklijke Philips N.V., Philips Healthcare, Nasiff Associates, Inc., LifeWatch AG, Schiller AG, Fukuda Denishi Co. Ltd. Spacelabs Healthcare, and Welch Allyn. Click To Reading More On Holter Monitor Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] Healthcare professionals have been keenly interested in the treatment of gastroesophageal reflux disease (GERD) and stomach & intestinal ulcer owing to its increasing prevalence. GERD is common health problem, which leads to serious medical complications and further huge medical expense in its diagnosis and treatment. The two most frequently observed symptoms associated with GERD are heartburn and acid regurgitation. Usually, over-the-counter antacids, proton pump inhibitor, and H-2 receptor blockers are used to decrease the effects of stomach acids or to block acid production.
Ranitidine is a histamine H2 antagonists and available as both over-the-counter (OTC) and prescription drug, indicated in the treatment of gastroesophageal reflux disease (GERD). Ranitidine decreases the acid production from stomach for up to 12 hours. Also, ranitidine is commonly used in erosive esophagitis, peptide ulcer disease, and Zollinger–Ellison syndrome. It could be taken orally or intravenously. To Access the Free Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/2131 The global ranitidine market size was valued at US$ 412.4 Mn in 2017, and is expected to witness a CAGR of 1.8% over the forecast period (2018 – 2026). Growing Research and Development (R&D) on Ranitidine is expected to Boost Market Growth Various government and private research organizations are increasingly engaged in research and development studies to increase the efficacy of ranitidine and examine possible potential of ranitidine to increase future scope of ranitidine market. Furthermore, various clinical trials are currently undergoing to identify and compare efficacy between ranitidine and other proton pump inhibitors such as esomeprazole and rabeprazole to measure gastric acid reduction in stomach. With the result of these studies, the efficacy of ranitidine is expected to improve and offer better treatment regimes in reducing excessive gastric acid production in the near future. Rising Cases of Various Gastric Ulcers and Digestive Diseases is expected to Increase Growth of the market High prevalence of gastroesophageal reflux disease (GERD), intestinal & stomach ulcers, esophagitis, heartburn, and other digestive diseases due to unhealthy lifestyle, changing dietary patterns will lead to increase in demand for ranitidine-based medications in the near future. According to Florida Hospital, 2018 U.S. data statistics, in the U.S. over 60 million adults suffer from acid reflux symptoms every month. Furthermore, the source states that each day an estimated 25 million of the 60 million adults suffers from acid reflux symptoms. Also, according to the same source, about 20% of people with acid reflux will develop gastroesophageal reflux disease (GERD) in the near future. Heartburn with or without regurgitation is identified as one of the prime symptoms of gastroesophageal reflux disease (GERD). According to World Gastroenterology Organization (WGO), 2015, prevalence of GERD is rapidly increasing worldwide, with differences reported in prevalence ranging from 2.5% to 6.6% in Eastern Asia while slightly higher up to 13.8% to 25.8% in North America. Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/ranitidine-market-2131 Key players operating in the global ranitidine market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Strides Pharma Science Limited (StridesShasun), Tocris Bioscience (R & D Systems), Merck KGaA, and Sun Pharmaceutical Industries Limited among others. Detailed Segmentation: Global Ranitidine Market, By Strength:
Global Ranitidine Market, By Form:
Global Ranitidine Market, By Route of Administration:
To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2131 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Erythrocyte sedimentation rate (ESR) analyzer measures the rate, at which the red blood cells or erythrocytes settle in a period of one hour. ESR is usually measured in millimeter per hour (mm/hour). An extremely high ESR value, which is one above 100 mm/hour may indicate the diseases such as multiple myeloma, hypersensitivity vasculitis, and temporal arteritis. ESR analyzer is a common hematological tester, which detects the non-specific inflammation, caused by active infection, cancer, heart disease, kidney disease, blood disease, diabetes, and collagen vascular disease. These analyzers are used in hospitals to measure the sedimentation rate of erythrocytes and red blood cells for reliable and accurate reading. The fully automated ESR analyzers are enable to give the fully automatic analysis of ESR. Semi-Automated ESR analyzers are not fully automatic rather certain operations of those instruments require manual intervention. The advantage of these instruments include smaller size, due to which they can be used in constrained spaces.
Global ESR Analyzer Market - Drivers Increasing number of infections leading to various health hazards will contribute to increasing number of ESR tests, which in turn will drive the global ESR analyzer market. According to the World Health Organization, in 2018, healthcare associated infection was about 10% and surgical site infections were 50%. ESR is one of the basic hematological test, which is performed to identify various disease conditions that would contribute to growth of global ESR analyzer market. Technological upgrades leading to development of automated ESR analyzers would also contribute to the global ESR analyzer market growth. Request A Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/2813 Furthermore, adoption of advanced semi-automatic and automatic ESR analyzers in the healthcare industry are among the prime factors driving the global ESR analyzer market growth. On the other hand, requirement of lesser workforce and is ultimately fueling the global ESR analyzer market growth. Increase in usage of ESR analyzers in hospitals, diagnostic laboratories, and academic institutions drives growth of the global ESR analyzer market. Moreover, manufacturers are developing advanced systems such as automated ESR analyzers to provide instant detection rate. For instance, in July 2018, Streck and Diesse Diagnostica Senese introduced the Cube 30 Touch, an automated instrument for high volume erythrocyte sedimentation rate testing in Ethylene diamine tetraacetic acid (EDTA) tubes. The analyzer produces ESR results directly from EDTA tubes without consuming the patient sample. Furthermore, in September 2013, Beckman Coulter, Inc., and IRIS Diagnostics announced the launch of the Alifax automated erythrocyte sedimentation rate (ESR) analysis system through a distribution agreement with Alifax S.r.l. Key players in the global ESR analyzer market are adopting distribution agreements that allow the company to enhance revenue in various regions. For instance, in March 2017, Sysmex America signed a distribution agreement with Alifax S.r.l. for its erythrocytes sedimentation rate products. Alifax ESR analyzers are an exciting addition in the Sysmex portfolio. In response to the market needs for quick results, the Alifax Test1 and Roller 20, a family of automated analyzers, offer ESR results in 20 seconds. Global ESR Analyzer Market - Regional Insights North America holds dominant position in the global ESR analyzer market, owing to increasing incidence of blood related diseases and presence of majority of the manufacturers in this region. Asia Pacific is expected to gain the highest growth rate during the forecast period, owing to increasing blood borne infections, and inadequate sanitation conditions, which lead to increase infections among population. Moreover, government focuses on the improvement in healthcare infrastructure and providing the better healthcare facilities to the population, which would propel growth of global ESR analyzer market in Asia Pacific. Global ESR Analyzer Market - Competitive Landscape Some of the key players operating in the global ESR analyzer market include ALCOR Scientific Inc., Thermo Fisher Scientific, Caretium Medical Instruments Co., LTD, Hospitex Diagnostics, Beckman Coulter Inc., Alifax, Perlong Medical, Streck, Diesse Diagnostica Senese S.p.A, and ELITech Group. Click To Reading More On ESR Analyzer Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected] A positron emission tomography (PET) - computed tomography (CT) scan reveals information about both the structure and function of cells and tissues in the body during a single imaging session. In recent times, majority of PET scans are performed on instruments that are combined with PET and CT scanners. The combined PET-CT scans provide images that identify the anatomic location of abnormal metabolic activity within the body. The combined scans have been shown to provide more accurate diagnoses than the two scans performed separately.
The diagnosis of various diseases such as cancer, heart diseases, and certain brain disorders require the use of both PET and CT scans. PET scanners measure metabolic activity, whereas CT scanners highlight anatomical features. The risk to poor superimposition of separate imaging is reduced and the hybrid PET-CT process lessens burden on the patient by simplifying the scanning process. The use of PET-CT scanner hybrids combine the strengths of two well-established imaging modalities and helps in accurate diagnosis, localizing, and monitoring of the disease. Moreover, PET-CT scanners can record the images in extremely short time (less than a minute). Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2169 The global PET-CT scanner device market size was valued at US$ 1.9 billion in 2017 and is expected to witness a CAGR of 5.1% over the forecast period (2018 – 2026). Increasing prevalence of chronic diseases and rising geriatric population is expected to drive the PET-CT scanner device market revenue Rising prevalence of infectious and chronic diseases such as cancer and heart disease across the globe and increasing demand for effective diagnostic systems is expected to drive the PET-CT scanner market size. According to the National Centre for Health Statistics, 2011, heart disease is the leading cause of death in the U.S., killing over 600,000 people each year. According to the International Agency for Research on Cancer (IARC), in 2012, an estimated 14.1 million new cancer cases were reported, globally. Among these, the most common form of cancer was lung cancer (13%), breast cancer (11.9%), and colorectal cancer (9.7%). According to the Centers for Disease Control and Prevention (CDC), February 2018 data, around 22,000 men and 9,000 women suffer from liver cancer, and around 16,000 men and 8,000 women die due to liver cancer, every year in the U.S. PET-CT Scanner Device Market - Regional Insights On the basis of region, the global PET-CT scanner device market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global PET-CT scanner device market, owing to rising number of traumatic brain injury cases in the U.S. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2013, around 282,000 people were diagnosed with brain injury and around 50,000 people died due to traumatic brain injury in the U.S. It is estimated to be a major cause of disability and death in the U.S. Get Full Access of This Business Report @ https://www.coherentmarketinsights.com/market-insight/pet-ct-scanner-device-market-2169 PET-CT Scanner Device Market - Competitive Landscape Key players operating in the global PET-CT scanner device market include General Electric Co., Hitachi, Ltd., Mediso Ltd., Koninklijke Philips N.V., PerkinElmer, Inc., Positron Corporation, Siemens AG, Shimadzu Corporation, Toshiba Corporation, and Yangzhou Kindsway Biotech Co. Ltd. Manufacturers are continually bringing in new PET/CT design. New technology enables more precise measurements of metabolic processes and data quantification, including assessment of cancerous tissue, neurologic disease, and cardiac blood flow (perfusion). Detailed Segmentation: Global PET-CT Scanner Device Market, By Detector Type:
Global PET-CT Scanner Device Market, By Setting:
Global PET-CT Scanner Device Market, By Application:
Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2169 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent progression of cystic fibrosis-related liver disorders. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover, it can improve long-term survival in patients with primary biliary cirrhosis.
Request Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2199 Significant improvement in liver health can be achieved through UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases. The global ursodeoxycholic acid market size was valued at US$ 457.3 million in 2017 and is expected to exhibit a CAGR of 10.1% over the forecast period (2018 – 2026). Increasing prevalence of gall stones and cystic fibrosis to propel the ursodeoxycholic acid market growth Ursodeoxycholic acid is being increasingly used for treatment of chronic cholestatic liver diseases. Increasing prevalence of cystic fibrosis and gall stones is the major factor driving growth of the global ursodeoxycholic acid market during the forecast period. According to the Cystic Fibrosis Foundation 2015 data, around 30,000 people suffered from cystic fibrosis in the U.S. Moreover, around 1,000 new cases of cystic fibrosis are diagnosed in the country, annually. According to the American Gastroenterological Association 2017 report, gallstones is affecting 10-15% of the U.S. population annually, which accounts for around 25 million people. Increasing research studies on ursodeoxycholic acid to bolster the market growth Increasing research studies conducted on application of ursodeoxycholic acid (UDCA) in other disease indications is expected to fuel growth of the global ursodeoxycholic acid market. According to the University of Sheffield August 2018 study, UDCA improves mitochondrial dysfunction, which is known to be a causative factor for both sporadic and familial Alzheimer’s disease. According to the Cure Parkinson’s Trust, U.K. 2018 article, researchers demonstrated that UDCA could protect dopamine cells grown in culture from apoptosis, or programmed cell death, by regulating a specific cell survival pathway. Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/ursodeoxycholic-acid-market-2199 Key Players Major players operating in the global ursodeoxycholic acid market include Dipharma Francis Srl, ERREGIERRE S.p.A., Grindeks, Industria Chimica Emiliana, Mitsubishi Tanabe Pharma Corporation, Zhongshan Belling Biotechnology Co., Glenmark Pharmaceutical Limited, Abil Chempharma Private Limited, Biotavia Labs Pvt Ltd, Daewoong Bio Inc., PharmaZell GmbH, and Suzhou Tianlu Bio-pharmaceutical Co., Ltd. Detailed Segmentation: Global Ursodeoxycholic Acid Market, By Dosage Form:
Global Ursodeoxycholic Acid Market, By Mode of Extraction:
Global Ursodeoxycholic Acid Market, By Application:
Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2199 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] 7/17/2019 Nonalcoholic Steatohepatitis Treatment Market Report Explored in Latest Research to 2026Read NowNonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.
Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine. Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2279 Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis. The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026). Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the nonalcoholic steatohepatitis treatment market revenue Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period. According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%. Get Full Access of This Business Report: https://www.coherentmarketinsights.com/market-insight/nonalcoholic-steatohepatitis-treatment-market-2279 Nonalcoholic Steatohepatitis Treatment Market - Regional Insights On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver. Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc. Detailed Segmentation: Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:
Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:
To Get Instant Access, Purchase Report Here: https://www.coherentmarketinsights.com/insight/buy-now/2279 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected] |
Details
Global Industry Research Experienced Professional Freelancer with a demonstrated history of working in the information technology and services industry. Skilled in Front Office, Customer Service, Marketing, Microsoft Office, and Social Media. Strong media and communication professional with a Bachelor of Commerce - BCom focused in Computer and Information Sciences and Support Services from Pune University. Archives
July 2020
Categories |